The Study
Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer.
This study looked at a group of lung cancer patients and found that some had certain gene changes, and those patients tended to live shorter lives. But it didn’t change anyone’s treatment—it just watched what happened. So we can’t say the gene changes caused the shorter life, just that they happened together.
Analysis score
Maximum 44 for a cross-sectional study.
Where the score came from
Scientists looked at lung cancer patients with advanced disease to see how often three specific gene changes (STK11, KEAP1, KRAS) appear and how long patients live after diagnosis.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 534 / 100
Quality score
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Patients with STK11 or KEAP1 mutations, especially together, lived significantly shorter lives than others, suggesting these mutations may make treatment less effective.
- 2STK11 mutation: 18% of patients, lived 6.6 months on average.
- 3KEAP1: 15%, lived 7.1 months.
- 4KRAS: 35%, lived 9.9 months.
- 5Patients with two or more mutations lived 6.1–6.7 months.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of Clinical Oncology
Year
2023
Authors
F. Dabbous, Ching-Yu Wang, D. Simmons, S. Huse, R. Jassim
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.